Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08052667 Monotherapy and Combination Therapy in Non-Muscle Invasive Bladder Cancer
NCT07206225Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Primary completion
- Jan 2030
- Modality
- Biologic
- Countries
- 6
01
Overview
Phase 1, open-label trial of PF-08052667 in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events up to 2 years and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
PF-08052667
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07206225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206225.